DR1-like element in human topoisomerase IIα gene involved in enhancement of etoposide-induced apoptosis by PPARγ ligand

Experimental Hematology

Volumn 31, Issue 4, 2003, Pages 300-308

  Kanbe, Eiki ^a   Abe, Akihiro ^a   Towatari, Masayuki ^a   Kawabe, Tsutomu ^a   Saito, Hidehiko ^a,b,c   Emi, Nobuhiko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c Aichi Juridical Found for Blood D   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CAMPTOTHECIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GYRASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; TROGLITAZONE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; GENE ACTIVITY; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR BINDING;

EID: 0037385036     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00003-1     Document Type: Article

References (62)

1. Nitiss J.L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim Biophys Acta. 1400:1998;63-81.
2. Tsai S.C., Valkov N., Yang W.M., Gump J., Sullivan D., Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet. 26:2000;349-353.
3. Roca J., Ishida R., Berger J.M., Andoh T., Wang J.C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A. 91:1994;1781-1785.
4. Wang J.C. DNA topoisomerases. Annu Rev Biochem. 65:1996;635-692.
5. Hochhauser D., Stanway C.A., Harris A.L., Hickson I.D. Cloning and characterization of the 5′-flanking region of the human topoisomerase II α gene. J Biol Chem. 267:1992;18961-18965.
6. Chen G., Templeton D., Suttle D.P., Stacey D.W. Ras stimulates DNA topoisomerase II α through MEK. a link between oncogenic signaling and a therapeutic target Oncogene. 18:1999;7149-7160.
7. Brandt T.L., Fraser D.J., Leal S., Halandras P.M., Kroll A.R., Kroll D.J. c-Myb trans-activates the human DNA topoisomerase II α gene promoter. J Biol Chem. 272:1997;6278-6284.
8. Sandri M.I., Isaacs R.J., Ongkeko W.M.et al. p53 regulates the minimal promoter of the human topoisomerase II α gene. Nucleic Acids Res. 24:1996;4464-4470.
9. Falck J., Jensen P.B., Sehested M. Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase II α gene. J Biol Chem. 274:1999;18753-18758.
10. Adachi N., Nomoto M., Kohno K., Koyama H. Cell-cycle regulation of the DNA topoisomerase II α promoter is mediated by proximal CCAAT boxes. possible involvement of acetylation Gene. 245:2000;49-57.
11. Isaacs R.J., Harris A.L., Hickson I.D. Regulation of the human topoisomerase IIα gene promoter in confluence-arrested cells. J Biol Chem. 271:1996;16741-16747.
12. Tolner B., Hartley J.A., Hochhauser D. Transcriptional regulation of topoisomerase II α at confluence and pharmacological modulation of expression by bis-benzimidazole drugs. Mol Pharmacol. 59:2001;699-706.
13. Furukawa M., Uchiumi T., Nomoto M.et al. The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase II α gene by heat shock. J Biol Chem. 273:1998;10550-10555.
14. Yoon J.H., Kim J.K., Rha G.B.et al. Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase II α gene promoter. Biochem J. 344:1999;367-374.
15. Lim K., Lee J.I., Yun K.A.et al. Reduced level of ATF is correlated with transcriptional repression of DNA topoisomerase II α gene during TPA-induced differentiation of HL-60 cells. Biochem Mol Biol Int. 46:1998;35-42.
16. Davies S.M., Robson C.N., Davies S.L., Hickson I.D. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem. 263:1988;17724-17729.
17. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A. 90:1993;2160-2164.
18. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 68:1992;879-887.
19. Tugwood J.D., Issemann I., Anderson R.G., Bundell K.R., McPheat W.L., Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11:1992;433-439.
20. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR γ 2. tissue-specific regulator of an adipocyte enhancer Genes Dev. 8:1994;1224-1234.
21. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem. 270:1995;12953-12956.
22. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ Cell. 83:1995;803-812.
23. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:1995;813-819.
24. Bannister A.J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 384:1996;641-643.
25. Yang X.J., Ogryzko V.V., Nishikawa J., Howard B.H., Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature. 382:1996;319-324.
26. Wolffe A.P., Pruss D. Targeting chromatin disruption. Transcription regulators that acetylate histones Cell. 84:1996;817-819.
27. Chen H., Tini M., Evans R.M. HATs on and beyond chromatin. Curr Opin Cell Biol. 13:2001;218-224.
28. Chawla A., Schwarz E.J., Dimaculangan D.D., Lazar M.A. Peroxisome proliferator-activated receptor (PPAR) γ adipose-predominant expression and induction early in adipocyte differentiation Endocrinology. 135:1994;798-800.
29. Xin X., Yang S., Kowalski J., Gerritsen M.E. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 274:1999;9116-9121.
30. Law R.E., Goetze S., Xi X.P.et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation. 101:2000;1311-1318.
31. Fu M., Zhu X., Wang Q.et al. Platelet-derived growth factor promotes the expression of peroxisome proliferator-activated receptor γ in vascular smooth muscle cells by a phosphatidylinositol 3-kinase/Akt signaling pathway. Circ Res. 89:2001;1058-1064.
32. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:1998;241-252.
33. Nagy L., Tontonoz P., Alvarez J.G., Chen H., Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ Cell. 93:1998;229-240.
34. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M.et al. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:1996;5336-5348.
35. Sears I.B., MacGinnitie M.A., Kovacs L.G., Graves R.A. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene. regulation by peroxisome proliferator-activated receptor γ Mol Cell Biol. 16:1996;3410-3419.
36. Ogura M., Hamaguchi M. Coagulation and fibrinolytic system of macrophages. Nippon Rinsho. 47:1989;545-549.
37. Morishita Y., Morishima Y., Ogura M., Nagai Y., Ohno R. Biochemical characterization of human myeloperoxidase using three specific monoclonal antibodies. Br J Haematol. 63:1986;435-444.
38. Morgan S.E., Beck W.T. Role of an inverted CCAAT element in human topoisomerase IIα gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells. Mol Pharmacol. 59:2001;203-211.
39. Firth J.D., Ebert B.L., Pugh C.W., Ratcliffe P.J. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes. similarities with the erythropoietin 3′ enhancer Proc Natl Acad Sci U S A. 91:1994;6496-6500.
40. Harris S.G., Phipps R.P. The nuclear receptor PPAR γ is expressed by mouse T lymphocytes and PPAR γ agonists induce apoptosis. Eur J Immunol. 31:2001;1098-1105.
41. Greene M.E., Blumberg B., McBride O.W.et al. Isolation of the human peroxisome proliferator activated receptor γ cDNA. expression in hematopoietic cells and chromosomal mapping Gene Expr. 4:1995;281-299.
42. Juge-Aubry C., Pernin A., Favez T.et al. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. J Biol Chem. 272:1997;25252-25259.
43. Padilla J., Kaur K., Cao H.J., Smith T.J., Phipps R.P. Peroxisome proliferator activator receptor-γ agonists and 15-deoxy-Δ(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells. J Immunol. 165:2000;6941-6948.
44. Bishop-Bailey D., Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12, 14-prostaglandin J2. J Biol Chem. 274:1999;17042-17048.
45. Ohta K., Endo T., Haraguchi K., Hershman J.M., Onaya T. Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 86:2001;2170-2177.
46. Sarraf P., Mueller E., Jones D.et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ Nat Med. 4:1998;1046-1052.
47. Elstner E., Muller C., Koshizuka K.et al. Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A. 95:1998;8806-8811.
48. Tontonoz P., Singer S., Forman B.M.et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci U S A. 94:1997;237-241.
49. Demetri G.D., Fletcher C.D., Mueller E.et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 96:1999;3951-3956.
50. Mueller E., Smith M., Sarraf P.et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci U S A. 97:2000;10990-10995.
51. Hong J.H., Okada K., Kusano T.et al. Reduced DNA topoisomerase II in VP-16 resistant mouse breast cancer cell line. Biomed Pharmacother. 44:1990;41-45.
52. Kubo T., Kohno K., Ohga T.et al. DNA topoisomerase II α gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Res. 55:1995;3860-3864.
53. Kawanami K., Nakamura T., Ono M.et al. Decreased DNA topoisomerase II α expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin. Oncol Res. 8:1996;197-206.
54. Kuriyama M., Tsutsui K., Ono Y.et al. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II α Neurol Med Chir (Tokyo). 37:1997;655-661. discussion 661-652.
55. Towatari M., Adachi K., Marunouchi T., Saito H. Evidence for a critical role of DNA topoisomerase IIα in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line. Br J Haematol. 101:1998;548-551.
56. Asano T., An T., Zwelling L.A., Takano H., Fojo A.T., Kleinerman E.S. Transfection of a human topoisomerase II α gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Oncol Res. 8:1996;101-110.
57. Zhou Z., Zwelling L.A., Ganapathi R., Kleinerman E.S. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIα gene transfer is independent of topoisomerase IIβ Br J Cancer. 85:2001;747-751.
58. Ogiso Y., Tomida A., Lei S., Omura S., Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 60:2000;2429-2434.
59. Kurz E.U., Wilson S.E., Leader K.B.et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase IIα expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther. 1:2001;121-131.
60. Goswami P.C., Roti Roti J.L., Hunt C.R. The cell cycle-coupled expression of topoisomerase IIα during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation. Mol Cell Biol. 16:1996;1500-1508.
61. Nakajima T., Kimura M., Kuroda K.et al. Induction of ubiquitin conjugating enzyme activity for degradation of topoisomerase II α during adenovirus E1A-induced apoptosis. Biochem Biophys Res Commun. 239:1997;823-829.
62. Mondal N., Parvin J.D. DNA topoisomerase IIα is required for RNA polymerase II transcription on chromatin templates. Nature. 413:2001;435-438.